S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages E232-E242

  Reeb, Ashley N ^a   Li, Wen ^a   Sewell, Will ^a   Marlow, Laura A ^b   Tun, Han W ^b   Smallridge, Robert C ^b   Copland, John A ^b   Spradling, Kyle ^a   Chernock, Rebecca ^c   Lin, Reigh Yi ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; MOK PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; S100A8 GENE; S100A9 GENE; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; THYROID CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; APOPTOSIS; CELL SURVIVAL; DISEASE COURSE; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; THYROID TUMOR; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CALGRANULIN A; CALGRANULIN B; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84928319162     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2988     Document Type: Article

References (21)

1. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22: 1104-1139.
2. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. 2003; 170: 3233-3242.
3. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins. J Immunol. 2013; 190: 794-804.
4. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005; 11: 5146-5152.
5. Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009; 8: 1368-1379.
6. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150: 165-178.
7. Ito Y, Arai K, Nozawa R, et al. S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma. Anticancer Res. 2009; 29: 4157-4161.
8. Marlow LA, D'Innocenzi J, Zhang Y, et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab. 2010; 95: 5338-5347.
9. Hasegawa K, Nakamura T, Harvey M, et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res. 2006; 12: 6170-6178.
10. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008; 456: 593-598.
11. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001; 130: 1028-1034.
12. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990; 66: 321-330.
13. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res. 2006; 312: 184-197.
14. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 2011; 9: 133-148.
15. Yin C, Li H, Zhang B, et al. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition. Breast Cancer Res Treat. 2013; 142: 297-309.
16. Arai K, Yamada T, Nozawa R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol. 2000; 17: 183-188.
17. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer. 2004; 40: 1179-1187.
18. Wang J, Cai Y, Xu H, et al. Expression of MRP14 gene is frequently down-regulated in Chinese human esophageal cancer. Cell Res. 2004; 14: 46-53.
19. Ghavami S, Rashedi I, Dattilo BM, et al. S100A8/A9 at low concentration promotes tumorcellgrowth via RAGE ligationand MAP kinase-dependent pathway. J Leukoc Biol. 2008; 83: 1484-1492.
20. Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29: 2035-2043.
21. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nature medicine. 2003; 9: 907-913.